Clinical trial
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic…
NCT00147238 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00147238 |
|---|---|
| Title | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast |
| Official title | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Bladder Cancer, Genitourinary Cancer, Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Ferumoxtran-10 (USPIO), MR lymphangiography |
| Enrollment | 10 |
| Start date | Jul 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: